background Thrombospondin-related anonymous protein (TRAP) is a prime candidate for a malaria vaccine. Antibodies to Plasmodium vivax TRAP (PvTRAP) occur upon natural infection while specific antigenic domains remain to be addressed.
Introduction
Malaria is a leading cause of morbidity and mortality in tropical and sub-tropical areas. Although the majority of disease burden is caused by Plasmodium falciparum, the infection of Plasmodium vivax can be chronic relapsing illness while severe complications have also been documented [1, 2] . To achieve malaria elimination, malaria vaccines could enhance currently available control measures that mainly combat anopheline vectors and malarial parasites.
Proteins on the surface of malarial sporozoites are targets for pre-erythrocytic vaccine development [3] .
Immunisation with radiation-attenuated sporozoites could elicit immunity that effectively impedes the establishment of infection [4, 5] . Subsequent studies have revealed that circumsporozoite protein (CSP) is immunogenic and abundantly expressed on the surface of malarial sporozoites [6] . However, vaccination trials using CSP-derived immunogens has conferred a limited clinical efficacy in field studies, suggesting that a more effective pre-erythrocytic stage vaccine requires incorporation of multiple protective immunogens [5, 7] .
Thrombospondin-related anonymous protein (TRAP) is a plasmodial glycosylated micronemal protein secreted during sporozoite motility and translocated to the sporozoite surface [8] [9] [10] . Malarial TRAP involves in the processes of sporozoite entry into mosquito salivary gland and human hepatocyte [11, 12] . Moreover, two extracellular portions of malarial TRAP, the von Willebrand A-domain and the thrombospondin repeats located in domains II and IV, respectively, are crucial for initial host cell adherence and stabilisation of adhesion/deadhesion during gliding mobility of sporozoites [13] . Importantly, naturally acquired antibodies against P. falciparum TRAP (PfTRAP) exhibited less parasite density among individuals in malaria hyperendemic areas, supporting the role of this molecule in eliciting protective immunity against malaria parasite [14] . Furthermore, immunisation of Aotus monkeys with P. vivax TRAP (PvTRAP)-derived peptide has conferred partial protection upon challenge infection with a heterologous parasite strain [15] .
PvTRAP exhibits microheterogeneity of sequences among isolates in which domains II and IV contained significantly greater number of nonsynonymous nucleotide substitutions than synonymous nucleotide substitutions, a hallmark of positive selection plausibly driven by host immune pressure [16] [17] [18] . Therefore, it remains to be addressed whether P. vivax-infected individuals in Thailand could mount anti-PvTRAP antibodies against antigens derived from these domains. Furthermore, we determined whether microheterogeneity of PvTRAP sequences could affect antibody recognition, an issue that could pose a major impediment to malaria vaccine efficacy. Results revealed that P. vivax-infected patients in Thailand possessed naturally acquired IgG antibodies to both domains II and IV of PvTRAP. Although a small proportion of serum samples from vivax malaria patients displayed variant-specific antibody responses, the majority of patients possessed cross-reactive antibodies to variant antigens of each domain.
Materials and methods

Ethics
Written informed consent was obtained from all participants or from their parents or guardians prior to blood sample collection. The study protocol was approved by the Institutional Review Board in Human Research of Faculty of Medicine, Chulalongkorn University, Thailand (IRB No. 303/56).
Blood and serum samples
Finger-prick blood samples were obtained from 80 P. vivax-infected patients in Tak and Ubon Rachathani provinces bordering Myanmar and Cambodia, respectively, in 2013 for sequence analysis of PvTRAP. For serological analysis, 246 venous blood samples were collected from acute P. vivax-infected patients in Tak (n = 50) and Ubon Ratchathani provinces (n = 196) during 2013 and 2014, comprising individuals aged 2-65 years (mean age, 30.9 years) and 82.9% male. Blood samples from 50 healthy individuals residing outside malaria endemic areas without history of malaria exposure were used as negative control. Plasma samples were separated and stored at À40°C until use.
DNA extraction, amplification and sequencing DNA was prepared from blood samples using QIAamp DNA minikit (Qiagen, Hilden, Germany). All DNA samples were confirmed for P. vivax infections by use of species-specific nested PCR as described previously [19, 20] . The complete PvTRAP sequences were determined from purified PCR products as previously reported [17] .
Recombinant proteins
The most common PvTRAP haplotypes from domain II and domain IV circulating in the study areas were selected for recombinant protein production including three other haplotypes from each domain. In total eight different recombinant proteins were produced in Escherichia coli cells as a polyhistidine tag in the C-terminus. The PvTRAP domain II spanning codons 30 and 239 was amplified by PCR using primers with artificially introduced Nde I restriction site in the forward primer and Xho I site in the reverse primer. The forward primer (PvTRAPFD2-F) sequence was 5 0 -CCCCCATATGGAC GAAGTGAAGTATAGTGA-3 0 (Nde I site underlined) and the reverse primer (PvTRAPFD2-R) was 5 0 -CCCCCTCGAGTTAGTTAGCAACTCTTTCCACTTC-3 0 (Xho I site underlined). Likewise, domain IV of PvTRAP encompassing codons 284 and 493 was amplified by PCR using the forward primer PvTRAPFD4-F and the reverse primer PvTRAPRD4-R whose sequences were 5 0 -CCCCCATATGGTGGAACCTGAGCCTCTGCC-3 0 (Nde I site underlined) and 5 0 -CCCCCTCGAGTTATTTG-TAGCCATTATTTGATGACTTC-3 0 (Xho I site underlined), respectively. Genomic DNA of P. vivax belonging to selected haplotypes was used as templates. The thermal cycling profile contained 94°C for 2 min, 35 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 2 min, and a final 72°C for 5 min. After digestion with NdeI and XhoI, the purified PCR products were ligated to the pET19b plasmid and transformed into E. coli BL21 Star (DE3) pLysS (Invitrogen, Carlsbad, CA, USA). Protein expression was induced with 0.2 mM of isopropyl-b-D thiogalactopyranoside (IPTG) at 30°C for 6 h. For recombinant proteins expressed in inclusion bodies, the cell pellets were resuspended in 20 mM Tris-HCl (pH 7.5), 10 mM EDTA, 1% Triton X-100 and 250 mM phenylmethylsulfonyl fluoride (PMSF), vortexed and sonicated on ice. After adding lysozyme (20 mg/ml), the lysates were incubated at 30°C for 30 min, sonicated on ice and washed with buffer containing 20 mM Tris-HCl (pH 7.5), 10 mM EDTA and 1% Triton X-100. The cell pellets were dissolved in solubilisation buffer containing 500 mM 3-(cyclohexyamino)-1 propanesulphonic acid pH 11, 0.15% N-lauroylsarcosine and 1 M DTT. Cell debris was removed by centrifugation. Refolding of the recombinant proteins was carried out by dialysing the solubilised inclusion bodies against 1 l of buffer containing 1 M TrisHCl (pH 8.5) and 0.1% DTT at 4°C for 3 h and overnight. Subsequent dialysis was done using dialysis buffer without DTT for 3 h and repeated thrice. Final dialysis was done against redox refolding buffer containing 1 M Tris-HCl (pH 8.5), 0.2 mM oxidised glutathione and 1 mM reduced glutathione at 4°C for 12 h. The purified proteins were aliquoted and kept at À40°C until use. For recombinant proteins expressed in soluble fraction, the pellets were resuspended in binding buffer containing 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5 mM imidazole and 250 mM PMSF. After vortexing and sonicating on ice, lysozyme solution was added, incubated at 30°C for 30 min and sonicated on ice. After centrifugation, the supernatant was subject to filtration through a 0.2 lm filter. The soluble protein was purified by using His Bind Resin column (Novagen, Germany) per manufacturer's protocol and kept at À40°C until use. Protein concentration was measured with the Bradford assay (Bio-Rad).
Enzyme-linked immunosorbent assay (ELISA)
All 246 P. vivax-infected serum samples were analysed by ELISA for total IgG antibodies against eight recombinant PvTRAP antigens. The 96-well PolySorp immunoplates (Nunc, Wiesbaden, Germany) were coated overnight at 4°C with 0.5 lg/well of recombinant PvTRAP protein in 0.1 M carbonate buffer (pH 9.6) and blocked for 2 h at room temperature with 3% skimmed milk in PBS buffer. The plates were washed and incubated with 100 ll of diluted individual plasma samples (1:400 dilution) in duplicate at room temperature for 1 h. After washing with PBST (phosphate buffered saline containing 0.5% Tween 20), the plates were incubated with horseradish peroxidase-conjugated goat anti-human IgG (Invitrogen) diluted to 1:1000 with 3% skimmed milk at room temperature for 1 h and washed with PBST. The enzymatic reaction was developed with O-phenylenediamine dihydrochloride-hydrogen peroxide (OPD; Sigma-Aldrich Co.) as a substrate and stopped with 2.5 N sulphuric acid. The absorbance at 490 nm was read using BIO-RAD iMark TM Microplate Reader (BIO-RAD, Japan) and the mean value of each pair of wells was calculated. The cut-off values were set as the mean OD490 plus three standard deviations (SD) of 50 negative control serum samples.
Data analysis
DNA sequences were aligned using the CLUSTAL X program implemented in the MEGA software [21] . B cell epitope prediction was done with Bepipred Linear Epitope Prediction server using the default option [22] . Differences in the proportions of IgG-positive serum samples were assessed with chi-square tests. Cross-reactivity between antibody responses to variant antigens was analysed by means of Spearman's rank correlation test.
Results
Distribution of PvTRAP haplotypes and predicted B cell epitopes
In total 73 of 80 isolates contained single PvTRAP haplotypes characterised by non-superimposed signals of eletropherogram. Thirteen and 16 amino acid haplotypes were identified in domain II and domain IV of PvTRAP, respectively (Tables 1 and 2 ). Isolate APH17 represented the most common haplotype for domain II. Domain IV contained 12 amino acid substitutions and isolate APH22 represented the most common haplotype that contained an insertion of proline, aspartic acid and serine between residues 382 and 383. Linear B cell epitopes were predominantly clustered in domain IV ( Figure S1 ).
Recombinant PvTRAP proteins from domain II and domain IV
Isolates APH14, APH17, APH22 and APH52 were used for protein expressions. The recombinant proteins derived from domain II (~25 kDa) and domain IV (~47 kDa) of PvTRAP were produced as inclusion bodies and soluble proteins, respectively (Figure 1) .
Prevalence of IgG antibody responses to PvTRAP antigens
All 246 serum samples were tested for total IgG antibodies to eight antigens from domains II and IV of PvTRAP. For domain II, APH14 antigen was most frequently recognised by IgG antibodies in 126 (51.2%) serum samples despite APH17 being the most prevalent haplotype of this domain in both endemic areas (Tables 1 and 3) . Although variation in the prevalence of IgG antibodies to each variant antigen of domain II was observed, the difference was statistically significant only for serum samples from Ubon Ratchathani (P = 0.008) which seems to be predominantly reactive toward APH14 antigen most commonly found among parasite population in the study area (Table 3 ). 24% and 33.2% of serum samples from 
Amino acid positions are after the Salvador I sequence. Dots are identical residues. 
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Tak and Ubon Ratchathani, respectively, recognised all four variants of domain II. However, a total of 63.8% of these samples were reactive to one of these variants (Table 3) . Meanwhile, the corresponding 246 serum samples displayed a higher prevalence of anti-IgG antibodies to domain IV than to domain II of PvTRAP in which APH22 antigen of domain IV was most frequently recognised (65.9%). However, variation in IgG antibody responses to each antigen of domain IV was not remarkable and the seropositive rates for each variant antigen were not significantly different (P = 0.73 and 0.56 for serum samples from Tak and Ubon Ratchathani, respectively; Table 4 ). Antibodies reactive to all four variant antigens of domain IV occurred in 58% and 53.6% of serum samples from Tak and Ubon Ractachathani, respectively. In total, 71.5% of serum samples were reactive to at least one variant antigen of domain IV (Table 4) . Based on seropositives to one variant antigen, 61.4% of serum samples gave concordantly positive or negative reactivity to both domains while the remaining samples (38.6%) yielded discordant results (Table 5) . Therefore, it seems that IgG antibody responses to domain II and domain IV occurred independently (P = 0.037). Taken together, the prevalence of IgG antibodies to one variant antigen from either domain II or IV was 87.75%. Although the serum samples from Ubon Rachathani gave slightly higher seropositive rates than those from Tak province (88.56% vs. 82%), the difference was not statistically meaningful (P = 0.24; Figure 2 ).
Cross-reactive and variant-specific antibodies to PvTRAP
Because a number of serum samples were reactive to all four variant antigens of domain II and domain IV (Tables 3 and 4) , it is intriguing to determine whether antibodies to these antigens were cross-reactive antibodies or non-cross-reacting subsets of the total antibody population. We made a pairwise comparison of antibody responses to these variant antigens, i.e. domain II variants were compared ( 1 and 7) , lysates after 6 h induction with IPTG (lanes 2 and 8), purified proteins from APH14 (lanes 3 and 9), APH17 (lanes 4 and 10), APH22 (lanes 5 and 11) and APH52 (lanes 6 and 12). Lane M is protein molecular weight standard. domain II and domain IV (Tables 3 and 4 ), implying that variant epitopes were recognised by the cross-reactive antibodies. Meanwhile, we made a pairwise comparison of serum samples reactive to one but not the other antigen from each domain and the number of amino acid difference between pair of tested antigens. A positive correlation was obtained for responses to antigens from domain II (Spearman's rank correlation test: r = 0.971, P = 0.01) but not for responses to domain IV antigens (r = À0.174, P = 0.75), suggesting that some populations of antibody reactive to domain II were variant-specific ( Figure 5 ).
Previous malaria exposure and anti-PvTRAP antibodies
Among 246 P. vivax-infected patients recruited in this study, reliable data on history of previous symptomatic malaria could be obtained from 70 patients who were diagnosed by local malaria clinics or district hospitals. Of these, 40 and 52 patients had IgG antibodies reactive to one variant antigen of domain II and domain IV antigens, respectively. The prevalence of IgG antibody responses to domain II antigens was similar between those having previous history of malaria exposure and those without prior malaria infection (Fischer's exact test; P = 0.810). However, there was a significantly higher prevalence of antibodies reactive to domain IV antigens among those who had previous malaria infections than those who did not (P = 0.007; Table 6 ).
Seroconversion after a short-term follow-up
Short-term follow-up serum samples collected at day 7, 14 and 21 after diagnosis and treatment (day 0) could be obtained from 22 patients. The duration of febrile symptoms prior to day 0 varied from 1 to 3 days. By day 2 after treatment, all patients were asymptomatic and parasitemia was not detectable by microscopy. Of these, antibodies to domain II and domain IV could be observed in 6 and 12 patients at day 0, respectively. An increase in >20% of O.D. values at day 21 in comparison to those at day 0 was found in two of six (33.3%) serum samples reactive to domain II antigens whereas 10 of 12 (83.3%) patients displayed elevated levels of antibody responses to domain IV antigens during the follow-up period. All eight seronegative serum samples to domain IV antigens at day 0 became seropositive at day 21. However, only 6 of 14 (42.9%) patients whose sera did not recognised domain II antigens became seropositive at day 21. At day 7, seroconversion from negative to positive reactivity to antigens from domain II and domain IV occurred in 50% and 62.5% of patients, respectively (Table 7) .
Discussion
A recent seroepidemiological study in Thailand has shown that no seropositivity to recombinant PvTRAP antigen was observed among 31 P. vivax-exposed individuals, of whom 17 were actively infected [23] . By contrast, our study revealed that 87.75% of 246 P. vivax-infected patients in Tak and Ubon Ratchathani provinces were seropositive to one of the eight recombinant proteins from either domain II or domain IV of PvTRAP. Although the reasons behind these discordant results remain unknown, it could stem from various factors such as differences in characteristics of epitopes on PvTRAP antigens used in the immunological assays, host genetic backgrounds and sample size. Nevertheless, naturally acquired anti-IgG antibodies to the recombinant PvTRAP antigen spanning amino acid residues 25 and 488 (including domains II and IV) have been detected in 42.4%, 38% and 44% of P. vivax-infected patients in Iran, Afghanistan and Pakistan, respectively [24] . Furthermore, our study has shown that the seropositive rate to one variant antigen of domain IV (72%) outnumbered that to domain II (63.4%), consistent with abundant occurrence of potential B cell epitopes in domain IV rather than in domain II ( Figure S1 ). It is noteworthy that 37.8% of serum samples displayed discordant results in reactivity to antigens from domains II and IV (P = 0.04), implying that differential antibody responses to these domains occurred among P. vivax-infected patients (Table 3) .
Therefore, the prevalence of seropositive rates to PvTRAP could also be affected by the target antigens used in each study.
Most surface proteins of malaria parasites exhibit antigenic polymorphism among isolates. Importantly, most immunogenic domains of these proteins are under positive selection [25] [26] [27] . Antigenic diversity could be an advantageous adaptive change of malaria parasites to evade host immune responses. For examples, a single amino acid substitution in the CS protein sequence of P. falciparum could alter the recognition by human T cells [28] while sequence variation in apical membrane antigen 1 could impede antibody recognition [29] . The present study reveals that both domain II and domain IV of PvTRAP were immunogenic upon natural infections and antibodies to each of these domains mainly belonged to cross-reactive subpopulations of antibody. It is noteworthy that the seropositive rates for antigens from domain IV among P. vivax-infected individuals were comparable. However, a small proportion of individuals in this study had variant-specific subpopulations of antibody predominantly to domain II of PvTRAP. Furthermore, the occurrence of non-cross-reactive antibodies seems to be positively correlated with the number of amino acid substitutions in tested antigens derived from domain II while this evidence was not observed in domain IV. Consistently, there was a bias towards positive reactivity of serum samples to domain II antigen belonging to the most common haplotype of P. vivax population in the study areas. It remains to be investigated whether cross-reactive and variant-specific antibodies to PvTRAP confer differential roles in protective immunity against P. vivax infections.
In hyperendemic areas of malaria, clinical immunity against malaria develops after repeated parasite exposures; thereby, infants and children bear the major burden of disease and are more vulnerable to severe malaria than adults who live in the same endemic areas [30] . Likewise, the induction of host protective immunity against malaria requires multiple immunisations [31] . The efficacy of malaria vaccines seem not to be prolonged but rather wanes after a certain period of protection [7] . Therefore, immunogens that generate boostable antibody responses could benefit vaccine design. A significant number of P. vivax-infected patients in this study who had previous history of symptomatic malaria infections could mount antibodies to domain IV of PvTRAP. On the contrary, prior malaria exposures seem not to affect antibody responses to domain II which could stem from the non-cross-reactive (or variant-specific) responses to antigens from this domain. A higher prevalence of non-cross-reactive antibodies to domain II than those to domain IV in this study could arise from co-existence of several PvTRAP haplotypes in a low transmission area like in Thailand [16, 17] ; thereby, acquiring all variantspecific antibodies to antigenic repertoire of PvTRAP could be compromised.
Dynamics of the antibody responses to malaria antigens could have impacts on clinical course of subsequent malaria infections in vaccination trials [32] . It has been widely perceived that antibody responses to malaria antigens are mostly short-lived after acute malaria infections; thereby, re-infections are commonly found in malaria endemic areas [33] . However, recent long-term follow-up studies have revealed that malaria exposure can induce both short-lived and long-lived IgG antibody-secreting cells leading to a rapid increase in antibody titres upon infection that decay rapidly within days or weeks later elicited by short-lived B cells, and the maintenance of relatively avid antigen-specific antibody titres for several years by memory B cell after resolution of acute infection [34, 35] . However, heterogeneity in antibody responses to malaria occurred among infected individuals and varied across populations. Meanwhile, the high avidity IgG1 and IgG3 antibodies to PvTRAP reportedly occurred among P. vivax-infected patients in Afghanistan, Iran and Pakistan could be in line with a feature of antigen-specific memory B cell responses [24] . Although longitudinal long-term follow-up has not been performed in our study, negative to positive seroconversion to PvTRAP antigens and rising antibody titres were observed in the majority of short-term follow-up patients. Therefore, analysis of a cross-sectional serum samples, especially during acute infection period, can substantially underestimate the seroprevalence of antibodies to PvTRAP antigens.
Conclusions
Plasmodium vivax-infected individuals in Thailand could mount IgG antibodies to domains II and IV of PvTRAP. Most of these naturally antibodies exhibited immunological cross-reactivity between variant antigens while a small proportion of serum samples were non-cross-reactive, especially to domain II. Previous malaria exposure could enhance seropositivity to domain IV. A number of serum samples became negative to positive seroconversion or increased in IgG antibody titres to both domains of PvTRAP. The high prevalence of naturally acquired cross-reactive IgG antibody responses to PvTRAP encourages vaccine design. Nevertheless, the biological relevance of naturally acquired humoral as well as cell-mediated immunity to PvTRAP in modulating P. vivax infection requires further investigation.
